Efferent therapy in the first-line drug treatment of metastatic colorectal cancer

Efferent therapy in the first-line drug treatment of metastatic colorectal cancer

The aim of this study is to analyse the efficacy of efferent therapy (hemosorption) as part of drug treatment in patients with metastatic colorectal cancer (mCRC) based on the use of standard first-line chemotherapy combined with the bevacizumab biosimilar. The study included 54 patients with histol...

Full description

Bibliographic Details
Main Authors: Z. S. Kotova, T. Yu. Semiglazova, I. A. Baldueva, D. H. Latipova, D. O. Yurlov, V. V. Semiglazov, G. M. Teletaeva, A. V. Novik, A. I. Semenova, S. A. Protsenko
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-07-01
Series:Медицинский совет
Subjects:
metastatic colorectal cancer
hemosorption
bevacizumab biosimilar
first-line treatment
Online Access:https://www.med-sovet.pro/jour/article/view/2554

Internet

https://www.med-sovet.pro/jour/article/view/2554

Similar Items